Proteomics International Laboratories Ltd
ASX:PIQ
Net Margin
Proteomics International Laboratories Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
40m AUD |
-188%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
151B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
141.8B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.5B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.4B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
195.8B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.2B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.5B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.3B EUR |
7%
|
Proteomics International Laboratories Ltd
Glance View
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Proteomics International Laboratories Ltd's most recent financial statements, the company has Net Margin of -188.1%.
You don't have any saved screeners yet